Rising rate of ocular allergies calls for eco-conscious interventions

Click here to read the Point/Counter to this Healio Exclusive.
Geographic distribution, prevalence and severity of ocular allergies are constantly changing and increasing.
Recent studies report rates of allergic conjunctivitis up to approximately 40% in North America and 20% in the world’s population. Allergy season is starting earlier and finishing later, symptoms are worsening, and people who never had allergies before are suddenly developing them well into adulthood.
“Our genetic makeup has remained essentially the same, so what has changed is important,” Leonard Bielory, MD, an

Diabetes community reacts to incident at ADA Scientific Sessions

The American Diabetes Association issued a video statement and apology from the CEO on June 10, after five attendees were removed from its annual Scientific Sessions.
On June 5, the first day of the annual meeting, five ADA members were escorted out of the New Orleans Ernest N. Morial Convention Center after handing out copies of an editorial published in Diabetes Care, an ADA journal. Video of the incident, originally published by MedPage Today, showed the attendees being escorted out of the convention center by security guards and police officers.
The editorial, which was published in April

Beneath the Surface: Debunking common sunscreen myths with Adewole S. Adamson, MD

Myths about sunscreen are pervasive, with many believing certain formulations damage coral reefs, disrupt the endocrine system and cause vitamin D deficiency.
In this Beneath the Surface video interview, Healio Dermatology Chief Medical Editor Joel M. Gelfand, MD, MSCE, FAAD, spoke with Adewole S. Adamson, MD, MPP, a dermatologist and health services researcher at Dell Medical School at the University of Texas, about the lack of evidence supporting these myths.
Certain destinations such as Hawaii, Thailand and Aruba ban the use of chemical sunscreens containing oxybenzone, octinoxate and

Tirzepatide may activate brown adipose tissue

CHICAGO — Tirzepatide may impact how the body burns energy by activating brown adipose tissue, according to results of a small study presented at ENDO 2026.
“Over the past 2 decades we have learned that brown adipose tissue is present and functional in adult humans and that its activity is closely linked to cardiometabolic health. In obesity, brown fat activity is markedly reduced, while growing evidence suggests its activation may improve metabolic parameters,” Rok Herman, MD, of the department of endocrinology, diabetes and metabolic diseases at University Medical Centre Ljubljana in

Self-expanding TAVR valve helps patients with small aortic annuli

In patients with small aortic annuli undergoing transcatheter aortic valve replacement, a self-expanding supra-annular valve was linked to less thrombosis and better hemodynamics at 3 years compared with a balloon-expandable valve, data show.
As Healio previously reported, in the main results of the SMART trial, patients assigned to TAVR with a self-expanding valve (Evolut Pro, Evolut Pro+ or Evolut FX, Medtronic) had similar clinical outcomes and better hemodynamic outcomes at 1 year compared with those assigned to TAVR with a balloon-expandable valve (Sapien 3 or Sapien 3 Ultra, Edwards

Burosumab improves physical function in X-linked hypophosphatemia

CHICAGO — Burosumab is tied to greater improvements in pain, stiffness and physical function than active vitamin D and phosphate salts among patients with X-linked hypophosphatemia, according to data presented at ENDO 2026.
Burosumab-twza (Crysvita, Kyowa Kirin), a monoclonal anti-fibroblast growth factor 23 antibody, was approved by the FDA as the first therapy to treat X-linked hypophosphatemia, a rare form of rickets, in 2018. In data from a prospective observational study, researchers assessed how burosumab impacted quality of life among people with X-linked hypophosphatemia compared with

Prior pulmonology visits linked to better odds for asthma follow-up care after ICU stay

ORLANDO — Children with asthma who already have seen a pulmonologist are more likely to get follow-up care after an ICU visit, according to a poster presented at the American Thoracic Society International Conference.
These findings indicate the positive impact that the early involvement of asthma specialists can have on outcomes for these patients, Akrishon L. Kirk, MD, a second-year pediatric pulmonology fellow at Children’s National, told Healio.
“One of the modifiable factors that affects whether or not an asthmatic is well controlled and whether or not they have increased morbidity or

Pharmacy organizations, NKF ‘reenergize’ shift to race-free eGFR

U.S. pharmacy organizations are advocating for the use of the 2021 race-neutral CKD-EPI equation for “medication-related decisions,” according to a consensus statement.
In conjunction with the National Kidney Foundation, pharmacy organizations wrote that the race-neutral CKD-EPI, as opposed to the Cockcroft-Gault estimated creatinine clearance equation, should be the “preferred creatinine-only equation for estimating kidney function in adults for medication-related decisions” with “results adjusted for body surface area.” The coalition called for this to be a “nationwide transition,” according

VIDEO: Survival in metastatic invasive lobular carcinoma differs by mutational signature

CHICAGO — In this video, Sherry Shen, MD, discusses her presentation at ASCO Annual Meeting on mutational signatures and related outcomes in metastatic invasive lobular carcinoma.
According to Shen, this subtype of breast cancer accounts for 10% to 15% of breast cancer diagnoses and is characterized by loss of the E-cadherin protein, which is responsible for cell-to-cell adhesion.
Shen and colleagues conducted a single-center cohort study to evaluate mutational signatures of metastatic invasive lobular carcinoma and how they affect outcomes.
“Patients with an APOBEC-dominant

VIDEO: ADT break may help therapy responders in metastatic prostate cancer

CHICAGO — In this video, Atish D. Choudhury, MD, PhD, discusses a study of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer who respond well to androgen receptor pathway inhibitors.
Findings from the single-arm, phase 2 A-DREAM trial were presented at ASCO Annual Meeting.
“We’re very interested in this idea moving forward, and we think that it will save a lot of our patients from unnecessary costs and toxicity,” Choudhury, medical oncologist at Dana-Farber Cancer Institute, told Healio.